newsfilter.io

NXGLNEXGEL, INC.

  1. Analyst Upgrades

    Maxim Group Downgrades NexGel to Hold

    Maxim Group analyst Naz Rahman downgrades NexGel from Buy to Hold. ...

  2. GlobeNewswire

    NEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVE

    LANGHORNE, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL") today announced a series of leadership, governance and strategic initiatives designed ...

  3. GlobeNewswire

    NEXGEL Reports Second Quarter 2026 Financial Results

    LANGHORNE, Pa., Aug. 17, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products ...

  4. GlobeNewswire

    NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th

    LANGHORNE, Pa., June 04, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content ...

  5. GlobeNewswire

    NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume Concentration

    The study concluded that NEXGEL's hydrogel patch significantly reduced laser plume generation and exposure during laser hair removal and the patch was associated with greater hair reduction and reduced pain compared to ...

  6. Earnings Call Transcripts

    NEXGEL, Inc's First Quarter 2026 Earnings Conference CallNEXGEL INC

    Good afternoon. I will be your conference operator today. At this time, I would like to welcome everyone to NextGel's Shareholder Update Conference Call. I will now turn the call over to Walter Pinto, Managing Director o ...

  7. GlobeNewswire

    NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical

    Appointment Supports Commercialization of Newly Launched BIONX Surgical Division, Formed Through Transformative Acquisition Expected to Significantly Scale Revenue LANGHORNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- ...

  8. GlobeNewswire

    NEXGEL To Report First Quarter 2026 Financial Results on May 15th

    Management Will Host a Conference Call at 12:00 P.M. ET on the Same Day LANGHORNE, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, ...

  9. GlobeNewswire

    NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors

    Sequence LifeScienceTM Led Financing to Close on Acquisition of Celularity with Strategic Investment of $5.5 Million LANGHORNE, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: ...

  10. GlobeNewswire

    NEXGEL Appoints Ian Blackman as Chief Financial Officer

    Veteran Financial and M&A Leader Appointed to Integrate Acquisition of Celularity, Scale the Business and Accelerate Growth LANGHORNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the ...

  11. Earnings Call Transcripts

    NEXGEL, INC'S FOURTH QUARTER 2025 EARNINGS CONFERENCE CALLNEXGEL INC

    Good afternoon. I will be your conference operator today. At this time, I would like to welcome everyone to NextGel's Shareholder Update Conference Call. Now I'll turn the call over to Walter Pinto, Managing Director of ...

  12. GlobeNewswire

    NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment

    Transaction expected to approximately triple NEXGEL's annual revenue to approximately $35 million and is expected to be immediately accretive to profitability Licensing and acquiring a diversified suite of 6 established ...

  13. GlobeNewswire

    NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET

    LANGHORNE, Pa., April 17, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, ...

  14. GlobeNewswire

    NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction

    LANGHORNE, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, ...

  15. GlobeNewswire

    NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity Transaction

    LANGHORNE, Pa., April 08, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, ...

  16. GlobeNewswire

    NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity

    LANGHORNE, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, ...

  17. GlobeNewswire

    NEXGEL to Report Fourth Quarter and Full Year 2025 Financial Results on March 31st

    Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., March 25, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, ...

  18. GlobeNewswire

    NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products

    Consideration for portfolio will consist of a $15 million upfront cash payment and potentially an additional $20 million in milestone payments based on net sales targets related to the portfolio Transaction expected to ...

  19. GlobeNewswire

    Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities

    Biovance, Biovance 3L, Natalin, Acelagraft, Interfyl and Centaflex licensed to NEXGEL are established commercial products widely used today in wound care, orthopedics and other indications.Three pipeline 510(k) medical ...

  20. GlobeNewswire

    NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products

    Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified suite of 6 ...

  21. GlobeNewswire

    NEXGEL Announces Financing of $1.797 Million Relating to an Acquisition Targeted to Close in the First Quarter of 2026, Subject to the Completion of Due Diligence

    LANGHORNE, Pa., Feb. 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, ...

  22. GlobeNewswire

    NexGelRx Receives Additional Investment from Eric Gruntfest of Diesis Holdings, LLC and Appoints Him as Board Observer and Strategic Advisor

    LANGHORNE, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, ...

  23. GlobeNewswire

    NEXGEL Announces Spin-Off of Drug Delivery Program into NexGelRx

    NEXGEL shareholders will receive a non-dilutive 19.99% equity interest in NexGelRx up to $8 million of capital investment in spin-off NEXGEL will also receive a 5% global royalty in perpetuity on products sold using its ...

  24. GlobeNewswire

    NEXGEL Reports Third Quarter 2025 Financial Results

    LANGHORNE, Pa., Nov. 11, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, ...

  25. GlobeNewswire

    NEXGEL to Report Third Quarter 2025 Financial Results on November 11th

    Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, ...